0001493152-24-010733.txt : 20240321
0001493152-24-010733.hdr.sgml : 20240321
20240321083025
ACCESSION NUMBER: 0001493152-24-010733
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240320
FILED AS OF DATE: 20240321
DATE AS OF CHANGE: 20240321
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Larson Douglas Quinton
CENTRAL INDEX KEY: 0001880132
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38892
FILM NUMBER: 24769575
MAIL ADDRESS:
STREET 1: BEYOND AIR, INC.
STREET 2: 900 STEWART AVENUE, SUITE 301
CITY: GARDEN CITY
STATE: NY
ZIP: 11530
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Beyond Air, Inc.
CENTRAL INDEX KEY: 0001641631
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 473812456
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 900 STEWART AVENUE
STREET 2: SUITE 301
CITY: GARDEN CITY
STATE: NY
ZIP: 11530
BUSINESS PHONE: 516-665-8200
MAIL ADDRESS:
STREET 1: 900 STEWART AVENUE
STREET 2: SUITE 301
CITY: GARDEN CITY
STATE: NY
ZIP: 11530
FORMER COMPANY:
FORMER CONFORMED NAME: AIT Therapeutics, Inc.
DATE OF NAME CHANGE: 20170117
FORMER COMPANY:
FORMER CONFORMED NAME: KokiCare, Inc.
DATE OF NAME CHANGE: 20150507
4
1
ownership.xml
X0508
4
2024-03-20
0
0001641631
Beyond Air, Inc.
XAIR
0001880132
Larson Douglas Quinton
C/O BEYOND AIR, INC.
900 STEWART AVENUE, SUITE 301
GARDEN CITY
NY
11530
0
1
0
0
Chief Financial Officer
0
Common Stock
2024-03-20
4
A
0
12048
1.66
A
27548
D
Warrants (right to buy)
2.25
2024-03-20
4
A
0
12048
0
A
2024-03-22
2027-03-22
Common Stock
12048
12048
D
Represents the common stock of Beyond Air, Inc. acquired by the reporting person in a registered direct offering on March 20, 2024, at a price of $1.66 per share.
Represents the warrants of Beyond Air, Inc. acquired by the reporting person in a registered direct offering on March 20, 2024. The warrants will be exercisable immediately upon issuance, at an exercise price of $2.25 per share and will have a term of three years following the date of issuance.
/s/ Douglas Quinton Larson
2024-03-21